Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive ...
Valbenazine is the first medication approved by the FDA for the treatment of adults with TD, a spectrum of hyperkinetic movement disorders often associated with antipsychotic therapy.
Tardive Dyskinesia Treatment | INGREZZA® (valbenazine) capsules
Learn how always once-daily INGREZZA® (valbenazine) capsules can be used to treat tardive dyskinesia (TD). See PI, including Boxed Warning, and Med Guide.
Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice
Jul 28, 2025 · Key Takeaways Tardive dyskinesia results from chronic dopamine-receptor blockade, causing involuntary movements, primarily in the oral-buccal-lingual areas. VMAT2 inhibitors, …
TD Treatment | INGREZZA® (valbenazine) capsules | HCP
Find treatment guidelines for tardive dyskinesia, including using INGREZZA as a first-line treatment option. See Prescribing Info, including Boxed Warning.
New 48-Week Remission Data on Ingrezza for the Treatment of Tardive ...
Mar 20, 2025 · Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once …
Valbenazine: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 12, 2025 · Valbenazine controls the symptoms of movement disorders but does not cure the conditions. Tardive dyskinesia is a nervous system disorder that causes repetitive, uncontrolled …
Neurocrine Data Show INGREZZA Delivers Higher VMAT2 Occupancy ...
Jan 15, 2026 · About INGREZZA® (valbenazine) Capsules and INGREZZA® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved …
Valbenazine Safe and Effective for Long-Term Treatment of Tardive ...
Apr 29, 2025 · A published paper pooling the KINECT-3 extension (NCT02274558) and KINECT-4 (NCT02405091) studies of valbenazine (Ingrezza; Neurocrine Biosciences) revealed that the therapy …
Valbenazine Phase 3 Study Confirms Safety, Efficacy for Tardive Dyskinesia
Jun 4, 2024 · Valbenazine can be a safe, tolerable, and highly effective long-term treatment option for people with tardive dyskinesia (TD), according to the results of a post hoc study led by manufacturer …
Treatment Recommendations for Tardive Dyskinesia - PMC
Data on tardive dyskinesia treatment are limited, and the best management strategy remains prevention. More long-term safety and efficacy data are needed for deutetrabenazine and valbenazine, and their …